Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses an analysis of chemotherapy administration and survival in soft tissue sarcoma.
Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses an analysis ofchemotherapy administration and survival in soft tissue sarcoma.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More